Alexandria Forbes, MeiraGTx CEO (Hollie Adams/Bloomberg via Getty Images)

J&J buys eye dis­ease gene ther­a­py from MeiraGTx, giv­ing the biotech the cash in­fu­sion it was seek­ing

John­son & John­son pur­chased a gene ther­a­py for X-linked re­tini­tis pig­men­tosa from MeiraGTx for $65 mil­lion up­front, the biotech an­nounced Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.